Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00163501 · ClinicalTrials.gov registry record · Phase 3

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

A Phase 3 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
600
Enrollment target

NCT00163501: Completed Phase 3 study, sponsored by AstraZeneca.

NCT00163501 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00163501, a Phase 3 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
600 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

Interventions

  • DRUG Ciclesonide

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2003-12
Est. Completion 2005-04
Phase Phase 3
AstraZeneca

1,285 total trials

What the finished NCT00163501 record still lists

NCT00163501 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 1 intervention - of which Ciclesonide is the first listed.

NCT00163501 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00163501 about?

NCT00163501 is a clinical study titled "Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)". The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.

What is the current status of trial NCT00163501?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2003-12. Estimated completion is 2005-04.

What interventions are being tested in trial NCT00163501?

The interventions under investigation include: Ciclesonide (DRUG).

Who is sponsoring clinical trial NCT00163501?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00163501's enrollment target sits among peer trials

600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00163501, the US trial registry maintained by the National Library of Medicine. NCT00163501 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.